Prevention of HIV/AIDS

Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective

Retrieved on: 
Wednesday, August 19, 2020
Medical specialties, Clinical medicine, Medicine, RTT, HIV/AIDS, Post-exposure prophylaxis, Prevention of HIV/AIDS, Rabies, Rabies in animals

The Study of KEDRAB (Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S.

Key Points: 
  • The Study of KEDRAB (Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S.
  • The Study Met its Primary Objective, Which Was to Confirm the Safety of KEDRAB in the Pediatric Population.
  • The primary objective of the study was to confirm the safety of KEDRAB in the pediatric population.
  • The Companys second leading product is KamRab, a rabies immune globulin (Human) for post-exposure prophylaxis against rabies infection.

China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

Retrieved on: 
Tuesday, August 11, 2020
Biotechnology, Hospitals, Pharmaceutical, Health, Medicine, Clinical medicine, Hepatotoxins, Health, RTT, Prevention of HIV/AIDS, Pre-exposure prophylaxis, Tenofovir disoproxil, Emtricitabine/tenofovir, Emtricitabine, Gilead Sciences, HIV/AIDS

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF).

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF).
  • The approval of Truvada for PrEP addresses an area of significant unmet need in the field of HIV prevention medicine in China.
  • Truvada for PrEP could play an important role in our response to the HIV epidemic and may help reduce the number of new HIV infections in China.
  • Since launching our operations in China in 2017, we have introduced a number of HIV treatments for people living with HIV.

ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1

Retrieved on: 
Thursday, August 6, 2020
AIDS, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Prevention of HIV/AIDS, GlaxoSmithKline, Pfizer, ViiV Healthcare, Treatment as prevention, HIV/AIDS, Dovato (dolutegravir/lamivudine), TANGO, ViiV Healthcare, GSK

At ViiV Healthcare, weve proven that with Dovato, adults living with HIV can reduce the number of ARVs they take every day without compromising efficacy or barrier to resistance.

Key Points: 
  • At ViiV Healthcare, weve proven that with Dovato, adults living with HIV can reduce the number of ARVs they take every day without compromising efficacy or barrier to resistance.
  • The approval of Dovato in adults who are virologically suppressed is based on the Week 48 results from the phase III TANGO study.
  • No participants on Dovato and one participant (
  • Dovato is approved for the treatment of HIV-1 in treatment-nave and virologically suppressed adults by the European Medicines Agency and additional regulatory authorities around the world.

ASTROGLIDE Takes Pleasure To The Next Level With TOY 'N JOY™ Personal Lubricant

Retrieved on: 
Friday, July 31, 2020
Chemical substances, Chemistry, Medical specialties, Personal lubricant, Vagina, HIV/AIDS, Prevention of HIV/AIDS, Sexual health, Lubricant, Condom, Female condom, Paraben

VISTA, Calif., July 31, 2020 /PRNewswire/ --BioFilm Inc., the makers of ASTROGLIDE , today in celebration of National Orgasm Day announced its newest personal lubricant: ASTROGLIDE TOY 'N JOY.

Key Points: 
  • VISTA, Calif., July 31, 2020 /PRNewswire/ --BioFilm Inc., the makers of ASTROGLIDE , today in celebration of National Orgasm Day announced its newest personal lubricant: ASTROGLIDE TOY 'N JOY.
  • Not only is ASTROGLIDE's TOY 'N JOY personal lubricant gentle on intimate areas, but it's also condom compatible, hypoallergenic and both glycerin and paraben free.
  • ASTROGLIDE's TOY 'N JOY personal lubricant is available in 5-oz.
  • No matter the need, ASTROGLIDE personal lubricants are formulated to help take people's sex lives to the next level.

UPDATE - Impressive Results From CytoDyn’s Phase 2 COVID-19 Trial

Retrieved on: 
Tuesday, July 21, 2020
Drugs, Health, Hepatotoxins, PRO 140, Medicine, Clinical research, Prevention of HIV/AIDS, Triple-negative breast cancer, Management of HIV/AIDS, Zidovudine, Placebo, CCR5 receptor antagonist

Scott Kelly, M.D., CytoDyns Chief Medical Officer, commented, We are very pleased with the safety results in the double-blinded, placebo-controlled study of the mild-to-moderate COVID-19 population.

Key Points: 
  • Scott Kelly, M.D., CytoDyns Chief Medical Officer, commented, We are very pleased with the safety results in the double-blinded, placebo-controlled study of the mild-to-moderate COVID-19 population.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.
  • CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.

Impressive Results From CytoDyn’s Phase 2 Covid-19 Trial

Retrieved on: 
Tuesday, July 21, 2020
Drugs, Health, Hepatotoxins, PRO 140, Medicine, Clinical research, Prevention of HIV/AIDS, Triple-negative breast cancer, Management of HIV/AIDS, Zidovudine, Placebo, CCR5 receptor antagonist

Scott Kelly, M.D., CytoDyns Chief Medical Officer, commented, We are very pleased with the safety results in the double-blinded, placebo-controlled study of the mild-to-moderate COVID-19 population.

Key Points: 
  • Scott Kelly, M.D., CytoDyns Chief Medical Officer, commented, We are very pleased with the safety results in the double-blinded, placebo-controlled study of the mild-to-moderate COVID-19 population.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.
  • CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.

Sexual Wellness Market Outlook and Forecast 2020-2025 Featuring LifeStyles, Church & Dwight, Diamond Products, Reckitt Benckiser, Okamoto Industries, Karex Berhad, Doc Johnson, and Many Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 21, 2020
Health, General Health, Articles, Human sexuality, Behavior, HIV/AIDS, Prevention of HIV/AIDS, Sexual health, Interpersonal relationships, Condom, RTT, Female condom, Sexual intercourse

The study considers the present scenario of the sexual wellness market and its market dynamics for the period 2019-2025.

Key Points: 
  • The study considers the present scenario of the sexual wellness market and its market dynamics for the period 2019-2025.
  • The online strategy is one of the most preferred modes for purchasing sexual wellness products among consumers.
  • In terms of volume, the male condom market constituted close to 99% of the sexual wellness market share in 2019.
  • There has been a rise in the level of awareness and experimentation of sexual wellness products in the region.

CytoDyn Files Application with Nasdaq for Uplist

Retrieved on: 
Wednesday, July 15, 2020
Hepatotoxins, Drugs, RTT, HIV/AIDS, Chemical substances, Management of HIV/AIDS, Prevention of HIV/AIDS, Zidovudine, PRO 140, CCR5 receptor antagonist

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented: While we realize the regulatory review of our application to uplist to Nasdaq will take several weeks, we believe the Company is well positioned for success.

Key Points: 
  • Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented: While we realize the regulatory review of our application to uplist to Nasdaq will take several weeks, we believe the Company is well positioned for success.
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.

IAVI and Scripps Research Join Efforts with the U.S. National Institutes of Health to Expedite Development of Globally Accessible and Affordable HIV Antibody Combination Products

Retrieved on: 
Thursday, July 9, 2020
Research, Women, Infectious diseases, Clinical trials, Philanthropy, AIDS, Fund Raising, Consumer, Health, Science, Medical specialties, Health, Medicine, International AIDS Vaccine Initiative, Prevention of HIV/AIDS, Reproductive health, Antibody, HIV, IAVI, Scripps Research, Serum Institute of India Pvt. Ltd. (Serum Institute), USAID

The combination products will be rigorously compared in preclinical and clinical trials to determine which combination is optimal for HIV prevention and potentially for treatment.

Key Points: 
  • The combination products will be rigorously compared in preclinical and clinical trials to determine which combination is optimal for HIV prevention and potentially for treatment.
  • IAVIs collaboration with Scripps Research and NIH will strengthen IAVIs ongoing partnership with the Serum Institute of India Pvt.
  • Ltd. (Serum Institute) to bring to licensure an affordable and globally accessible monoclonal antibody prevention product for HIV.
  • IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis.

Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)

Retrieved on: 
Saturday, July 4, 2020
Biotechnology, AIDS, Hospitals, Health, Pharmaceutical, Hepatotoxins, RTT, Specialty drugs, Articles, Chemical substances, Biotechnology, Prevention of HIV/AIDS, Gilead Sciences, Management of HIV/AIDS, HIV, Zidovudine

Lenacapavir is an investigational agent that is being developed as a component of a long-acting regimen in combination with other antiretroviral agents.

Key Points: 
  • Lenacapavir is an investigational agent that is being developed as a component of a long-acting regimen in combination with other antiretroviral agents.
  • Lenacapavir disrupts HIV capsid, a multimeric shell that is essential to viral replication, at multiple stages throughout the viral life cycle.
  • All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
  • Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.